Generic Drug Challenges Prior to Patent Expiration


The Hatch-Waxman Act established the current regime for competition between brandname and generic drugs. We examine a feature of the Act that has generated significant controversy, yet received little systematic attention. “Paragraph IV” challenges are a mechanism for generic drug makers to challenge the patents of brand-name drug makers as a means to… (More)


11 Figures and Tables

Cite this paper

@inproceedings{Hemphill2009GenericDC, title={Generic Drug Challenges Prior to Patent Expiration}, author={C. Scott Hemphill and Bhaven N. Sampat and Scott Hemphill}, year={2009} }